Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 37,675 shares in stock options and 25,300 RSUs [1][2] Group 1: Stock Options and RSUs - The stock options have an exercise price of $41.45 per share, equal to the closing price on November 10, 2025 [2] - Stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder in 36 equal monthly installments, contingent on continued employment [2] - RSUs will also vest over four years in equal annual installments starting on the one-year anniversary, subject to continued employment [2] Group 2: Company Overview - Crinetics Pharmaceuticals is focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs [3] - The company specializes in discovering and developing therapies targeting G-protein coupled receptors (GPCRs) with tailored pharmacology [3] - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have inadequate surgical responses [4] Group 3: Pipeline and Development - The company has a deep pipeline with over 10 disclosed programs, including atumelnant, which is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [4] - Additional discovery programs target various endocrine conditions, including neuroendocrine tumors, Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [4]